GSK opts to co-develop experimental rheumatoid arthritis drug

GlaxoSmithKline has triggered an option under a 1996 joint partnership deal with Human Genome Sciences to co-develop LymphoStat-B, an experimental drug for rheumatoid arthritis. The two companies will split the costs of Phase III and Phase IV trials and share in the revenues from any successful product launch.

- read this report from the Washington Business Journal for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.